Dr Leung is the founder, Chairman and Chief Executive Officer of SinoMab BioScience Limited. Currently, he is also a Member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited.
Dr Leung has over 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. He was the first scientist who successfully developed humanised anti-CD22 antibody and introduced the concept of “Functional Humanisation”. He held positions as an Executive Director of a US leading antibody-drug conjugate company, the Managing Director of The Hong Kong Institute of Biotechnology Limited, and Adjunct Professor at Fudan University, The Army Medical University (formerly known as the Third Military Medical University) and The Air Force Medical University (formerly known as the Fourth Military Medical University) in Mainland China, as well as The Chinese University of Hong Kong (CUHK) and The Hong Kong University of Science and Technology.
Dr Leung obtained his bachelor’s and master’s degrees in biochemistry, as well as EMBA from CUHK. He earned his D.Phil. in molecular biology from the University of Oxford in the UK in May 1989. He was also a postdoctoral fellow at Yale University in the US from July 1990 to June 1992.